NCT05374603 - Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

August 30, 2025

Study Completion Date

August 30, 2025

Conditions

Lung Cancer

Interventions

DRUG

Savolitinib

Savolitinib combine with Durvalumab

DRUG

Durvalumab

savolitinib plus durvalumab

Trial Locations (16)

100021

Research Site, Beijing

100039

Research Site, Beijing

200030

Research Site, Shanghai

250021

Research Site, Jinan

310003

Research Site, Hangzhou

310009

Research Site, Hangzhou

315100

Research Site, Ningbo

325000

Research Site, Wenzhou

330006

Research Site, Nanchang

400010

Research Site, Chongqing

410011

Research Site, Changsha

430022

Research Site, Wuhan

430030

Research Site, Wuhan

450000

Research Site, Zhengzhou

650118

Research Site, Kunming

CN-100730

Research Site, Beijing